Compare Stocks

→ The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLIF Appili Therapeutics	$0.03	$0.03	$0.02 ▼ $0.08	$3.64M	-0.3	266,875 shs	87,134 shs
BCTXF BriaCell Therapeutics	$2.24 +2.3%	$2.84	$3.25 ▼ $17.50	$1.73M	1.09	1,859 shs	29,085 shs
EVFM Evofem Biosciences	$0.02	$0.02	$0.01 ▼ $3.75	$929K	-1.12	778,788 shs	555,899 shs
PKPH Peak Pharmaceuticals	$5.50	$2.88	$0.52 ▼ $9.12	$2.16M	0.54	9,053 shs	4 shs
SPRCY SciSparc	$4.00 -19.0%	$4.00	$2.75 ▼ $12.25	$4.15M	-0.08	10,035 shs	12,500 shs

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLIF Appili Therapeutics	0.00%	-4.45%	+30.37%	+26.82%	-3.79%
BCTXF BriaCell Therapeutics	-3.45%	+3.70%	-21.40%	-43.43%	-67.58%
EVFM Evofem Biosciences	-4.70%	+0.71%	-21.98%	-59.31%	-99.44%
PKPH Peak Pharmaceuticals	0.00%	+29.41%	+86.76%	+146.64%	+23.87%
SPRCY SciSparc	0.00%	0.00%	0.00%	0.00%	0.00%

Protect Yourself While There’s Still Time … (Ad)

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLIF Appili Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BCTXF BriaCell Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EVFM Evofem Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PKPH Peak Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SPRCY SciSparc	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLIF Appili Therapeutics	N/A	N/A	N/A	N/A
BCTXF BriaCell Therapeutics	N/A	N/A	N/A	N/A
EVFM Evofem Biosciences	2.00	Hold	N/A	N/A
PKPH Peak Pharmaceuticals	N/A	N/A	N/A	N/A
SPRCY SciSparc	N/A	N/A	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLIF Appili Therapeutics	$280K	12.99	N/A	N/A	($0.05) per share	-0.60
BCTXF BriaCell Therapeutics	N/A	N/A	N/A	N/A	($4.55) per share	N/A
EVFM Evofem Biosciences	$18.22M	0.05	$1.68 per share	0.01	($2.64) per share	-0.01
PKPH Peak Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
SPRCY SciSparc	N/A	N/A	$2.65 per share	1.51	$1.38 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLIF Appili Therapeutics	-$6.99M	-$0.04	N/A	N/A	N/A	-456.86%	N/A	-229.96%	6/21/2024 (Estimated)
BCTXF BriaCell Therapeutics	-$3.68M	-$3.84	N/A	∞	N/A	N/A	N/A	-786.77%	N/A
EVFM Evofem Biosciences	$52.98M	-$7.62	N/A	∞	N/A	290.81%	-90.20%	331.20%	4/26/2024 (Estimated)
PKPH Peak Pharmaceuticals	-$160K	N/A	0.00	∞	N/A	N/A	N/A	-159.55%	N/A
SPRCY SciSparc	-$3.48M	$14.94	0.27	N/A	N/A	N/A	N/A	N/A	N/A

Latest EVFM, PKPH, APLIF, BCTXF, and SPRCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/27/2024	Q4 2023	EVFM Evofem Biosciences	N/A	-$0.44	-$0.44	-$0.44	N/A	$4.84 million
2/13/2024	Q3 2024	APLIF Appili Therapeutics	-$0.01	-$0.01	N/A	N/A	N/A	$0.36 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLIF Appili Therapeutics	N/A	N/A	N/A	N/A	N/A
BCTXF BriaCell Therapeutics	N/A	N/A	N/A	N/A	N/A
EVFM Evofem Biosciences	N/A	N/A	N/A	N/A	N/A
PKPH Peak Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SPRCY SciSparc	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLIF Appili Therapeutics	N/A	0.46	0.46
BCTXF BriaCell Therapeutics	N/A	0.07	0.07
EVFM Evofem Biosciences	N/A	0.13	0.10
PKPH Peak Pharmaceuticals	N/A	0.15	0.15
SPRCY SciSparc	N/A	11.05	2.25

Ownership

Institutional Ownership

Company	Institutional Ownership
APLIF Appili Therapeutics	N/A
BCTXF BriaCell Therapeutics	0.10%
EVFM Evofem Biosciences	0.22%
PKPH Peak Pharmaceuticals	N/A
SPRCY SciSparc	N/A

Insider Ownership

Company	Insider Ownership
APLIF Appili Therapeutics	11.84%
BCTXF BriaCell Therapeutics	N/A
EVFM Evofem Biosciences	0.21%
PKPH Peak Pharmaceuticals	18.40%
SPRCY SciSparc	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
APLIF Appili Therapeutics	8	121.27 million	106.91 million	Not Optionable
BCTXF BriaCell Therapeutics	5	772,000	N/A	Not Optionable
EVFM Evofem Biosciences	37	55.46 million	53.85 million	Not Optionable
PKPH Peak Pharmaceuticals	1	392,000	320,000	Not Optionable
SPRCY SciSparc	2	1.04 million	N/A	Not Optionable

EVFM, PKPH, APLIF, BCTXF, and SPRCY Headlines

Source	Headline
	Latest News for SciSparc Stock (NASDAQ:SPRC) benzinga.com - April 11 at 10:51 PM
	Top 10 Hot Young OnlyFans & Spicy Young OnlyFans Models laweekly.com - March 27 at 7:21 PM
	Spicy Paloma pbs.org - February 27 at 8:57 AM
	Pokemon Indigo Disk Crispin guide – How to make a spicy sandwich and how to beat Crispin videogamer.com - January 3 at 7:39 PM
	Your Body on Spicy Food: The Good and Bad Ways It Affects Your Health everydayhealth.com - September 23 at 4:51 PM
	Teen’s death after spicy chip challenge halts sales, unleashes concerns pennlive.com - September 12 at 9:00 PM
	Snack company removes spicy ‘One Chip Challenge’ product after teen’s death washingtonpost.com - September 10 at 4:01 PM
	22 Spicy Perfumes For Fall 2023 That Smell Cozy & Comforting bustle.com - September 1 at 2:15 PM
	A Spicy Regenerative Reciever hackaday.com - June 7 at 1:12 AM
	Grilled Oysters With Spicy Garlic Butter and Parmesan Bread Crumbs wsj.com - May 20 at 8:38 AM
	Clearmind Medicine Inc. (CMND) ca.finance.yahoo.com - May 6 at 9:51 AM
	Jake Gyllenhaal Chases His Spicy Wings With a Classic Watch gq.com - April 21 at 11:54 PM
	SciSparc Shares Rise 22% on Joint Venture Milestone marketwatch.com - February 19 at 11:18 PM
	SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Reached First Milestone ... eagletribune.com - February 19 at 11:18 PM
	Why SciSparc Shares Are Moving During Friday's Session benzinga.com - February 19 at 11:18 PM
	Roasted eggplant with spicy tahini: Get the recipe! today.com - September 27 at 9:33 PM
	SciSparc Provides Updates Upon Conclusion of 2021 victoriaadvocate.com - December 31 at 6:18 PM
	SciSparc Awarded Three Patents For Its Novel Compounds and Methods finance.yahoo.com - September 7 at 5:15 PM
	SciSparc Ltd.: SciSparc Announces Completion of Corporate Rebranding and Launch of New Website finanznachrichten.de - August 29 at 8:55 PM
	SciSparc Ltd. ADR barrons.com - August 19 at 7:48 AM
	SciSparc Announces Completion of Corporate Rebranding and Launch of New Website finance.yahoo.com - August 4 at 12:08 PM
	SciSparc Announces Positive Topline Results For Proprietary Pain Management Compound In Pre-Clinical Study finance.yahoo.com - August 2 at 12:24 PM
	SciSparc Ltd oneidadispatch.com - July 31 at 8:01 PM
	Ironwood (IRWD) Hits 52-Week High, Can the Run Continue? msn.com - July 29 at 12:07 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Appili Therapeutics

OTCMKTS:APLIF

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.

BriaCell Therapeutics

OTCMKTS:BCTXF

BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

Evofem Biosciences

NASDAQ:EVFM

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Peak Pharmaceuticals

OTCMKTS:PKPH

Peak Pharmaceuticals, Inc. manufactures and markets pharmaceutical level products containing phytocannabinoids, an abundant and pharmaceutically active component of industrial hemp for the prevention and alleviation of various conditions and diseases. The company was founded on December 18, 2007 and is headquartered in Scottsdale, AZ.

SciSparc

OTCMKTS:SPRCY

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. SciSparc Ltd. has an agreement with Procaps to develop and commercially manufacture SCI-110, as well as CannAmide, a palmitoylethanolamide compound in softgel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to perform a pre-clinical study for the evaluation of SCI-210 drug development program for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv, Israel.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial